Experimental MegaLT injection targets dangerous low platelets in early trial
NCT ID NCT06534255
First seen Jun 26, 2026 · Last updated Jul 08, 2026 · Updated 3 times
Summary
This early-phase trial tests a new cell therapy called MegaLT for people with dangerously low platelet counts that don't improve after radiation, chemotherapy, or stem cell transplant. Only 10 participants will receive the injection at different doses to check safety and how the body handles it. The study is not yet recruiting and focuses on finding a safe dose, not proving it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MegaLT injection (a cell therapy)
- What this could lead to
- If it works, this could point toward a new treatment for dangerously low platelet counts that don't respond to standard care.
- What could go wrong
- This is a very early, tiny Phase 1 trial with only 10 people. It primarily checks safety, not effectiveness. The treatment may not work or could cause side effects like graft-versus-host disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY THROMBOCYTOPENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)
Hefei, Anhui, 230036, China